Applying the D50 disease progression model to gray and white matter pathology in amyotrophic lateral sclerosis.

ABSTRACT: Therapeutic management and research in Amyotrophic Laterals Sclerosis (ALS) have been limited by the substantial heterogeneity in progression and anatomical spread that are endemic of the disease. Neuroimaging biomarkers represent powerful additions to the current monitoring repertoire but have yielded inconsistent associations with clinical scores like the ALS functional rating scale. The D50 disease progression model was developed to address limitations with clinical indices and the difficulty obtaining longitudinal data in ALS. It yields overall disease aggressiveness as time taken to reach halved functionality (D50); individual disease covered in distinct phases; and calculated functional state and calculated functional loss as acute descriptors of local disease activity. It greatly re

SUBMITTER: Steinbach R 

PROVIDER: S-EPMC6940701 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature